The manufacturer of Remdesivir, an antiviral drug that has shown promise in treating COVID-19, has set the price of a 5-day course of treatment for a U.S. patient at $2,340, Reuters reported.
As previously reported by The Inquisitr, Remdesivir has been around for decades and has been used to treat Ebola, another potentially-fatal illness caused by a virus. Back in April, its manufacturer, Gilead Pharmaceuticals, announced that one limited study of about 400 patients showed that half of the sickened patients who were given the drug were discharged from the hospital within 14 days; some were discharged in as little as 5 days.
At the time, Aruna Subramanian, a lead investigator of the study, called the results “encouraging.”
“These data are encouraging as they indicate that patients who received a shorter, 5-day course of remdesivir experienced similar clinical improvement as patients who received a 10-day treatment course,” she said.
0 comments :
Post a Comment